ロード中...
Phase II Study of the Src Kinase Inhibitor Saracatinib (AZD0530) in Metastatic Melanoma
BACKGROUND: Src kinases are activated in melanoma, and inhibition of Src kinase activity has preclinical anti-tumor effects. Targeting this pathway could therefore have therapeutic activity in patients with metastatic melanoma. PATIENTS AND METHODS: We conducted a multi-center, open-label study of t...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3600382/ https://ncbi.nlm.nih.gov/pubmed/23151808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9897-4 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|